SEC Tracker
Get the app

Possible new OTLK shares

OTLKDilution

Known so far: no new shares from the prospectus covers read · shelf room about $9.0M · not yet read: warrants, converts, options, ATM.

Shelf room

  • Room today about $9.0M
  • One third of float $9.0M ($26.9M float, Mar 31, 2025)
  • Sold off it, 12 months nothing
How this is worked out

Shelf room about $9.0M on the S-3 of Jul 17, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $26.9M public float stated as of Mar 31, 2025, $9.0M, nothing sold off it in the last 12 months. Sources: S-3 Jul 17, 2026, effective Jul 21, 2026 · public float, as of Mar 31, 2025.

What could become new Outlook Therapeutics (OTLK) shares, from its 10-Q, 10-K, S-3 or 424B filings.

Read so far: the cover share count (243.4M shares, +448% from 44.4M on Aug 11, 2025). Not read yet: warrants, convertible notes, options and RSUs and an ATM program. Read them on EDGAR: the latest 10-Q · S-3 shelf filings.

Shares outstanding

243M

Dec 2024 to Aug 2026: from 24.9M to 243M.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.